Demands by patients, market pressures, and changing delivery models have brought to the fore the urgency to address whether subspecialization is necessary and entirely feasible.
Vipal Durkal, MD
Advertisement
Articles by Vipal Durkal, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Vopimetostat Plus Daraxonrasib Yields 82% ORR in MTAP-Deleted PDAC
2
Personalized mRNA Vaccine Intismeran Plus Pembro Cuts Melanoma Recurrence
3
Sunvozertinib Now Available in US for EGFR Exon 20 Insertion NSCLC
4
Rilvegostomig Combo Helped Some Patients Avoid Chemotherapy in Early Breast Cancer
5